RASSF1A gene methylation and its clinical significance in leukemia patients

Abstract

Abstract: Objective　To research Ras association domain family 1A（RASSF1A） gene promoter region methylation in bone marrow of leukemia patients and its clinical significance. Methods　Methylation of RASSF1A gene promoter region was detected by methylation specific polymerase chain reaction（MS-PCR） in the bone marrow of 86 leukemia patients，and the difference of different kinds of leukemia was analyzed. A total of 60 non-leukemia subjects were enrolled as controls. Results　Twelve of 86（13.95%） leukemia patients had RASSF1A gene promoter region methylation. No methylation was found in bone marrow of the control group，and there was a statistical significance（P＜0.05）. RASSF1A gene methylation ratio in lymphoid leukemia（23.1%） was higher than that in myeloid leukemia（6.4%）（P＜0.05）. Conclusions　Leukemia patients have RASSF1A gene methylation. The ratio of RASSF1A gene methyaltion in lymphoid leukemia is obviously higher than that in myeloid leukemia. RASSF1A gene methyaltion may be a significant parameter for diagnosis and genotyping of patients with leukemia.

Key words: Ras association domain family 1A gene, Leukemia, Methylation, Biomarker

CHEN Weiqun;HUANG Chen;ZHAN Xiyan;LIU Shuiyi;YU Jie;ZHANG Hongmei;LU Zhongxin . RASSF1A gene methylation and its clinical significance in leukemia patients[J]. , 2012, 27(7): 554-556.

References

[1]Dunwell T，Hesson L，Rauch TA，et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers [J]. Mol Cancer，2010，9：44.
[2]Richter AM，Pfeifer GP，Dammann RH. The RASSF proteins in cancer；from epigenetic silencing to functional characterization [J]. Biochim Biophys Acta，2009，1796（2）：114-128.
[3]Kurkjian C，Kummar S，Murgo AJ. DNA Methylation：its role in cancer development and therapy[J]. Curr Probl Cancer，2008，32（5）：187-235.
[4]Wang J，Wang B，Chen X，et al. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma：a systematic review and meta-analysis [J]. Carcinogenesis，2011，32（3）：411-416.
[5]Hu L，Chen G，Yu H，et al. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma [J]. Hepatol Int，2010，4（1）：423-432.
[6]Wang T，Liu H，Chen Y，et al. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma [J]. J Exp Clin Cancer Res，2009，28：160.
[7]Kang S，Kim HS，Seo SS，et al. Inverse correlation between RASSF1A hypermethylation，KRAS and BRAF mutations in cervical adenocarcinoma [J]. Gynecol Oncol，2007，105（3）：662-666.
[8]Ma L，Guo Q，Ma Y，et al. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers [J]. Eur J Gynaecol Oncol，2009，30（4）：370-374.
[9]Martins AT，Monteiro P，Ramalho-Carvalho J，et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions [J]. Breast Cancer Res Treat，2011，129（1）：1-9.
[10]Harada K，Toyooka S，Maitra A，et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines[J]. Oncogene，2002，21（27）：4345-4349.
[11]Johan MF，Bowen DT，Frew ME，et al. Aberrant methylation of the negative regulators RASSFIA SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia[J]. Br J Haematol，2005，129（1）：60-65.
[12]Avramouli A，Tsochas S，Mandala E，et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia[J]. Leuk Res，2009，33（8）：1130-1132.

[1]	GUO Yuanyuan, SONG Hui, ZHANG Lin. Correlation between serum Sema4D，fibrinogen-to-albumin ratio and prognosis in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2025, 40(8): 769-774.
[2]	GAO Xiantong, YAO Qianqian, RU Lijuan. Establishment and clinical application evaluation of early warning model for acute pancreatitis complicated with AKI [J]. Laboratory Medicine, 2025, 40(8): 775-781.
[3]	Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of Shanghai University of Traditional Chinese Medicine Shanghai Center for Clinical Laboratory, Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine Clinical Laboratory Society of Chinese Association of Integrative Medicine, Tumor Immunology Branch of Shanghai Society for Immunology Molecular Diagnostics Society of Shanghai Medical Association. Expert consensus on non-invasive laboratory diagnosis for hepatic fibrosis [J]. Laboratory Medicine, 2025, 40(7): 625-641.
[4]	HUANG Ren, SHI Weizhong, LU Renquan, GUO Lin, WANG Yanchun. Combined determination of Septin9 gene methylation and SDC2 gene methylation in auxiliary diagnosis of colorectal cancer [J]. Laboratory Medicine, 2025, 40(6): 519-524.
[5]	SHI Fangjing, HU Shanshan, LUO Xinguo, ZHU Yan, YU Fangquan, YE Hongwei. Expression of programmed death-1/programmed death-ligand 1 in chronic lymphocytic leukemia patients and its correlation with T lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(6): 592-595.
[6]	MA Jingyun, WANG Mengmeng, XIONG Boyu, DAI Zhuowen, PAN Yueyue, WANG Qiong. Research progress in phenotypic characteristics and treatment efficacy evaluation of acute promyelocytic leukemia variants [J]. Laboratory Medicine, 2025, 40(6): 606-614.
[7]	LIU Min, SUN Hengjuan, DU Chengkan, XIA Min, JIANG Linlin, WENG Wenhao, ZHANG Hong. Laboratory analysis of 6 cases of acute megakaryocytic leukemia in children [J]. Laboratory Medicine, 2025, 40(5): 484-488.
[8]	TANG Jiemei, WANG Binbin, LIU Na, TANG Gusheng. Influence of concomitant gene mutation on acute myeloid leukemia patients with RUNX1::RUNX1T1 fusion [J]. Laboratory Medicine, 2025, 40(2): 186-191.
[9]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[10]	DONG Yihan, LIU Shiming, WANG Yong, YUE Dan, WANG Rui. Research progress of exosome extraction and identification in renal cancer [J]. Laboratory Medicine, 2025, 40(11): 1118-1125.
[11]	LUO Yuanmei, LIU Chang, CHEN Lilong, LI Zhenzhang, YUE Yubiao, LI Yang, XU Lingqing. Acute promyelocytic leukemia diagnosis assisted by YOLOV8 deep learning model [J]. Laboratory Medicine, 2025, 40(10): 998-1003.
[12]	LIU Mengna, WANG Hongling, BAI Ping, CAI Yu, LI Li. Research progress on laboratory diagnosis and treatment of ETP-ALL [J]. Laboratory Medicine, 2025, 40(1): 1-7.
[13]	WANG Hongling, CAI Yu, LIU Mengna, BAI Ping. Clinical characteristic analysis of ETP-ALL patients with POX positive rate>3% [J]. Laboratory Medicine, 2025, 40(1): 20-24.
[14]	GUO Fengxia, HU Bing, SHA Yanhua. Role of methyltransferase-like protein 14 in patients with coronary heart disease [J]. Laboratory Medicine, 2025, 40(1): 54-58.
[15]	DING Jing, ZHANG Chunling, WANG Xiaorui, LI Huidan, WANG Hongling, LIU Weiling, LIN Lihui, LI Li. Laboratory diagnosis and prognostic factor analysis of core binding factor-related acute myeloid leukemia [J]. Laboratory Medicine, 2024, 39(7): 673-681.